NCT03853317 2024-08-09
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
ImmunityBio, Inc.
Phase 2 Terminated
Clinical Trials
4 trialsNCT02465957 2024-05-02
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
ImmunityBio, Inc.
Phase 2 Terminated
NCT02989844 2023-11-03
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT03050216 2023-07-18
QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
Masonic Cancer Center, University of Minnesota
Phase 2 Completed